LingMou Medical Secures Tens of Millions in Series A Funding to Accelerate Global Expansion of Domestic Flexible Endoscopy Solutions

VCBeat has learned at the earliest opportunity that a provider of department-level solutions for flexible endoscopyHangzhou LYNMOU Medical Technology Co., Ltd. (hereinafter referred to as“LYNMOU”）Announced the completion of tens of millions of RMBSeries A financing. This round was led byUnity VenturesLead investor,Chengshu FenghuaCo-investment, existing shareholdersHaibang FenghuaAdditional Investment,LEAP CAPITALServed as the exclusive financial advisor for this round.

This round of financing will accelerate the commercialization and academic promotion of the company’s flexible endoscopy systems both domestically and internationally, while further strengthening and supplementing its endoscopic product portfolio to establish itself as a top-tier Chinese brand in the flexible endoscopy sector.

Drawing on the management team’s extensive experience in the field of digestive endoscopy, LYNMOU continues to explore and develop a new generation of domestically produced flexible endoscopes. Leveraging the team’s exceptional execution capabilities, its independently developed Alioth series electronic endoscopy system received official approval from the National Medical Products Administration (NMPA) in May 2024, achieving this milestone in just two years.

This product breaks through traditional technological frameworks, leveraging self-developedAll-electric transmission technology significantly enhances the clinical stability of the product;also proposed“Full-Scenario Imaging” Concept: Four Specialized Light Imaging Modes—HLI, SVI, TCI, and DHIComprehensively address complex imaging needs, from diagnosis to treatment.Among these, the DHI (Deep Red Light Imaging) technology breaks the import monopoly. As a domestic first with patented intellectual property rights, it provides bleeding point identification during surgical procedures, assisting surgeons in rapidly locating blood vessels to achieve hemostasis, thereby realizing a new clinical application for domestically produced equipment.

Despite the severe challenges posed by a short-term slowdown in procurement demand due to changes in the domestic environment, LYNMOU has still won the recognition of numerous clinical experts and hospitals through its robust clinical performance. Meanwhile, LYNMOU actively participates in academic forums, having organized nearly 100 large-scale academic conferences and hands-on training workshops across China, thereby extending the benefits of advanced achievements to a broad base of physicians and patients and accelerating the market penetration of domestically produced products.

In overseas markets, LYNMOU has simultaneously deployed its sales team and channel infrastructure, establishing local partnerships and sales networks in multiple countries. At international exhibitions and conferences such as APDW 2024 and Arab Health 2025, the LYNMOU team engaged in extensive exchanges with professionals from around the world, with experts highly praising LYNMOU’s endoscopes.

The company is on the verge of obtaining multiple international regulatory certifications, which are expected to further accelerate the overseas deployment of its products. In the future, the company will also actively engage in international exchanges and cooperation to promote the continuous advancement and development of global digestive endoscopy technology, making significant contributions to improving the diagnosis and treatment of digestive system diseases worldwide.

Regarding securing this round of financing,LYNMOU ManagementThis financing round marks the capital market’s recognition of the innovation capabilities of domestically produced high-end medical devices. Building on a solid foundation of clinical applications in China, LYNMOU is enhancing the competitiveness and market penetration of domestic endoscopes. We sincerely thank our existing and new investors for their steadfast support. This financing serves not only as a milestone but also as a new starting point. We are committed to advancing product iterations with superior performance, accelerating commercialization, and improving team execution efficiency, thereby introducing high-quality products to both domestic and international markets, facilitating procedures for more surgeons, and benefiting more patients.

Wang Xiao, Founder of Unity Venture CapitalStatement: Leveraging its profound expertise in optics, structural mechanics, and systems engineering, LYNMOU has built a highly competitive product portfolio. Its multidisciplinary team is well-positioned to capitalize on industry cycle opportunities, and its business model has achieved initial validation in both domestic and international markets. We highly recognize LYNMOU’s innovation capabilities in technology and products, and are optimistic about the strategic synergies it will realize through the near-term realization of domestic policy dividends and its mid-to-long-term global expansion. We look forward to LYNMOU emerging as a new industry leader at an early date, benefiting more physicians and patients.

Gu Guan, Partner at Chengshu Fenghua FundIt indicates that the demand for digestive system cancer screening in China has not been fully met, with the three major Japanese endoscopy manufacturers long monopolizing the Chinese market and maintaining a share of over 80%. Driven by the dual forces of “overall volume growth” and “import substitution,” the potential of gastrointestinal endoscopy is expected to be fully unleashed, making it a rare category in the medical device sector that features both substantial market space and high entry barriers. The core team of LYNMOU possesses unique and comprehensive industry experience spanning R&D, mass production, and global commercialization, demonstrating its strength during the initial commercialization phase of its products in 2024. We have long monitored and remained optimistic about the gastrointestinal tract sector, and we are honored to partner with LYNMOU, committing to accompany and support the company in becoming a significant player in the global endoscopy field.

Li Jun, Investment Director of Hangzhou Haibang FenghuaStatement: In 2024, LYNMOU successfully achieved a milestone leap, transitioning its core products from regulatory approval to scaled mass production and clinical installation. Leveraging robust foundational technological expertise, its product portfolio rapidly seized market opportunities through stable capacity ramp-up. We highly recognize LYNMOU’s coherent strategic execution across “technology validation–mass production breakthrough–market coverage.” We are optimistic about its ability to continuously increase market penetration amid the policy dividends of domestic substitution and resonating global demand, setting an industry benchmark for translating technological breakthroughs into commercial success, thereby ensuring that advanced innovations continue to benefit patients and healthcare professionals alike.

Hu Yuqi, Head of Life Sciences at LEAP CAPITALStatement: LYNMOU, through its bidirectional innovation model of “demand-driven R&D and clinical feedback-led iteration,” precisely addresses pain points in endoscopic diagnosis and treatment. Its forward-looking technologies effectively empower improvements in clinical diagnostic and therapeutic efficiency, garnering substantial positive clinical feedback. We remain firmly optimistic about the company’s strategic vision—evolving from domestic substitution to global expansion—and its continuously iterated, all-scenario diagnostic and therapeutic capabilities. We look forward to LYNMOU’s continued efforts to promote technological accessibility and standard upgrades in the field of digestive endoscopy, injecting more efficient and sustainable innovative momentum into the global digestive health ecosystem.

Since its establishment in 2011, Unity Venture Capital has consistently focused on structural investment opportunities driven by technological transformation, standing as one of the few early-stage technology VCs in China that have remained active, leading, and continuously evolving. Unity Venture Capital aspires to be a value discoverer with future insights, identifying and supporting outstanding entrepreneurs to help nascent sparks grow into great enterprises of the era.

We excel at identifying opportunities at the intersection of “computing+” disciplines and in cross-sector integration areas. Our investment stages cover Angel, Pre-A, and Series A rounds, with our capabilities consistently validated across sectors such as hard tech, AI, advanced manufacturing, new energy, new materials, and biotechnology. Unity Venture Capital has invested in over 200 portfolio companies, serving as an early-stage investor in listed companies and unicorns including 36Kr (KRKR.US), QingCloud (688316.SH), Airdoc (02251.HK), Tangee, Zhonghe Yunke, and Momenta. More than ten projects have achieved valuation increases of over 100-fold, and the subsequent financing rate for our portfolio companies exceeds 80%.

Jiuhe manages five RMB-denominated funds and one USD-denominated fund, with entrusted capital primarily sourced from market-oriented fund-of-funds, leading listed companies, Chinese and foreign family offices, founders of renowned domestic and international internet companies, and government guidance funds.

Chengshu Capital focuses on growth-stage and early-stage investments in the consumer healthcare, medical devices, and life sciences sectors. Its management team comprises pioneers and builders in China’s capital markets and healthcare equity investment, bringing extensive industry resources and capital market expertise. With a deep understanding of corporate growth dynamics, the firm is committed to continuously empowering portfolio companies and creating long-term, sustainable value for investors. Guided by its investment philosophy of “Focus, Growth, and Long-Term,” Chengshu Capital identifies enterprises with significant growth potential at the early and mid-stages, supporting their development during critical periods through capital and strategic resources. By maintaining long-term partnerships with outstanding companies and entrepreneurs and increasing its commitment over time, Chengshu Capital serves as a co-creator of long-term, sustainable value.

Haibang Fenghua was founded by Zhejiang Haibang Investment, a renowned equity investment institution in Zhejiang Province, together with its entire investment management team. The company primarily focuses on early- to mid-stage equity investments in sectors such as life and health, the digital economy, and new materials. Adhering to the investment philosophy of “Technology + Talent,” we firmly believe that technology changes the world and are committed to supporting visionary, entrepreneurial founders driven by lofty ideals.

LEAP CAPITAL, established in 2019, is committed to becoming the most trusted value-added technology investment bank for entrepreneurs. It provides private placement financial advisory, strategic consulting, and innovation incubation services to companies from the angel stage through Pre-IPO rounds, helping them rapidly establish a leading capital advantage in their respective sectors. Adhering to the philosophy of DVA (Deep-Value-Add), LEAP CAPITAL continuously delivers comprehensive empowerment to corporate development from strategic, capital, and resource perspectives. Over its five years of operation, LEAP CAPITAL has successfully risen to become one of China’s leading technology investment banks, leveraging its outstanding multidisciplinary team, extensive industry experience, and top-tier operational capabilities. To date, it has assisted over 120 companies in completing more than 200 private financing transactions, with a cumulative transaction volume exceeding RMB 40 billion.